Last reviewed · How we verify
usage oral angiogenesis inhibitor
At a glance
| Generic name | usage oral angiogenesis inhibitor |
|---|---|
| Sponsor | Radboud University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer (PHASE2)
- Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer (PHASE1, PHASE2)
- Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (PHASE2)
- Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers (PHASE1, PHASE2)
- RegoNivo vs Standard of Care Chemotherapy in AGOC (PHASE3)
- First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer (PHASE2)
- Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial (PHASE1)
- Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: